Elicio Therapeutics (ELTX) Net Cash Flow (2020 - 2026)

Elicio Therapeutics (ELTX) has reported Net Cash Flow for 7 consecutive years, with $8.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Cash Flow rose 179.85% year-over-year to $8.3 million; the trailing twelve-month figure through Jun 2026 stood at $1.3 million (down 93.03% YoY), and the FY2025 full-year result was -$273000.0, down 105.28% from the prior year.
• Net Cash Flow rose to $8.3 million in Q2 2026 per ELTX's latest filing, from -$3.6 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $23.5 million in Q3 2024 and bottomed at -$15.7 million in Q1 2022.
• Historically, Net Cash Flow has averaged $771055.6 across 5 years, with a median of -$443000.0 in 2024.
• The sharpest annual moves came in 2024 and 2026: Net Cash Flow surged 554.16% in 2024, then plunged 1831.1% in 2026.
• Over 5 years, Net Cash Flow stood at $3.8 million in 2022, then sank by 176.06% to -$2.9 million in 2023, then tumbled by 195.85% to -$8.6 million in 2024, then jumped by 77.22% to -$2.0 million in 2025, then surged by 527.95% to $8.3 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered $8.3 million, -$3.6 million, and -$2.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.